SG11201708393UA - Sprinkle formulations of acamprosate - Google Patents
Sprinkle formulations of acamprosateInfo
- Publication number
- SG11201708393UA SG11201708393UA SG11201708393UA SG11201708393UA SG11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA
- Authority
- SG
- Singapore
- Prior art keywords
- acamprosate
- sprinkle formulations
- sprinkle
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708393UA true SG11201708393UA (en) | 2017-11-29 |
Family
ID=57217823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708393UA SG11201708393UA (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (https=) |
| EP (1) | EP3291800A4 (https=) |
| JP (2) | JP7026347B2 (https=) |
| KR (1) | KR102790656B1 (https=) |
| AU (1) | AU2016258624B2 (https=) |
| HK (1) | HK1252003A1 (https=) |
| IL (1) | IL255343B2 (https=) |
| SG (1) | SG11201708393UA (https=) |
| WO (1) | WO2016179252A1 (https=) |
| ZA (1) | ZA201708037B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357469B2 (en) | 2015-02-18 | 2019-07-23 | Aston University | Diagnostic assay and treatment for preeclampsia |
| SG11201708393UA (en) | 2015-05-04 | 2017-11-29 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| HK1255584A1 (zh) * | 2015-08-04 | 2019-08-23 | Confluence Pharmaceuticals, Llc | 使用阿坎酸及d-环丝胺酸的联合疗法 |
| IL270654B2 (en) * | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| EP4406479A4 (en) | 2021-09-24 | 2025-05-07 | Sumitomo Bakelite Co.Ltd. | Brain wave detection electrode, brain wave measurement device, and brain wave measurement method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| DE1073432T1 (de) | 1998-04-14 | 2002-02-07 | The General Hospital Corp., Boston | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| US20050042277A1 (en) * | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| JP2010532331A (ja) | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| CA2781830C (en) | 2009-02-12 | 2018-03-27 | Indiana University Research & Technology Corporation | Materials and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| MX346203B (es) * | 2010-09-28 | 2017-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior. |
| TR201809351T4 (tr) | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
| DK3272342T3 (da) * | 2011-03-23 | 2021-06-07 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AU2015217796B2 (en) | 2014-02-11 | 2020-04-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| SG11201708393UA (en) | 2015-05-04 | 2017-11-29 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
-
2016
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
- 2016-05-04 KR KR1020177033137A patent/KR102790656B1/ko active Active
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en not_active Ceased
- 2016-05-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10709668B2 (en) | 2020-07-14 |
| EP3291800A1 (en) | 2018-03-14 |
| US20190046458A1 (en) | 2019-02-14 |
| KR102790656B1 (ko) | 2025-04-02 |
| JP7026347B2 (ja) | 2022-02-28 |
| JP2018515506A (ja) | 2018-06-14 |
| AU2016258624B2 (en) | 2021-07-29 |
| EP3291800A4 (en) | 2018-09-26 |
| IL255343B2 (en) | 2024-10-01 |
| ZA201708037B (en) | 2020-03-25 |
| IL255343A0 (en) | 2017-12-31 |
| HK1252003A1 (zh) | 2019-05-10 |
| KR20170142180A (ko) | 2017-12-27 |
| WO2016179252A1 (en) | 2016-11-10 |
| JP2021155434A (ja) | 2021-10-07 |
| IL255343B1 (en) | 2024-06-01 |
| AU2016258624A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3270960A4 (en) | Vector formulations | |
| IL265856A (en) | Preparations for the administration of aflornithine | |
| ZA201708037B (en) | Sprinkle formulations of acamprosate | |
| SG11201803029WA (en) | Novel occlusive formulations | |
| PL3474822T3 (pl) | Preparaty brincydofowiru | |
| HUE064651T2 (hu) | A bedaquilin késleltetett hatású formulái | |
| IL268678B (en) | Formulas of 1-amino-1-cyclopropane-carboxylic acid | |
| GB201522764D0 (en) | Formulations of phosphate derivatives | |
| IL256400A (en) | Therapeutic uses of berberine formulations | |
| IL272857A (en) | Cofanalisib formulations | |
| EP3277256A4 (en) | COMPOSITIONS FOR HAIR TREATMENT | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| ZA201803032B (en) | Pharmaceutical compositions of dimethyl fumarate | |
| IL258420A (en) | Stable formulations of fingolimod | |
| GB201805338D0 (en) | Cosmetic formulations | |
| GB201504482D0 (en) | Novel formulations | |
| SI3490577T1 (sl) | Kožni sestavki, ki obsegajo turmerone | |
| GB2539454B (en) | Cosmetic compositions | |
| AU2015900283A0 (en) | Uses of effervescent formulations | |
| AU2016904621A0 (en) | Improved uses of new formulations | |
| GB201621277D0 (en) | Formulations | |
| GB201621867D0 (en) | Novel formulations of aprepitant | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations |